Effects of the human pulmonary surfactant protein-C (SP-C, SP-CL16(6-28) on surface activities of surfactants with various phospholipids

被引:6
作者
Otsubo, E [1 ]
Takei, T [1 ]
机构
[1] Mitsubishi Pharma Inc, Res Ctr, Chiba 2920812, Japan
关键词
surfactant protein-C; SP-CL16(6-28); surface activity; various phospholipid;
D O I
10.1248/bpb.25.1303
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We previously reported that a human analogue of pulmonary surfactant protein-C (SP-C, SP-CL16(6-28), with 23 residues was the most active analogue in a reconstituted lipid mixture and had the shortest chain among the poly-leucine-analogues examined. There has been little research on the chemical components of synthetic lung surfactants (SLSs). In the present study, we attempted to compare SLS with various phospholipids in surface activity. That is, SP-CL16(6-28) plus various phosphatidylglycerols (PG) were tested for surface activity in a Langmuir-Wilhelmy surface balance (WSB) apparatus and pulsating bubble surfactmeter (PBS). Further, SLSs were examined for biological properties using an animal model of surfactant deficiency, infant respiratory distress syndrome (IRDS), in vivo. Palmitoyl-oleoyl-phosphatidylglyceroI (POPG)-SLS exhibited minimum and maximum surface tensions of 1.7 mN/m and 28.6 mN/m in WSB and 8.5 mN/m and 36.2 mN/m in PBS, respectively. Moreover, in the IRDS model, POPG-SLS remarkably improved the lung volume (LV) of a premature lagomorph fetus at LV30 cmH(2)O and LV5 cmH(2)O. That is, a significant improvement equal to the LV of a fullterm fetus was observed. The level of LV exhibited respiratory improvement equivalent to surfactant-TA. SLS seemed comparable in surface activity with Surfacten(R) (Surfactant-TA), a modified surfactant preparation which has been used for the treatment of RDS.
引用
收藏
页码:1303 / 1306
页数:4
相关论文
共 16 条
[1]   SURFACE PROPERTIES IN RELATION TO ATELECTASIS AND HYALINE MEMBRANE DISEASE [J].
AVERY, ME ;
MEAD, J .
AMA JOURNAL OF DISEASES OF CHILDREN, 1959, 97 (05) :517-523
[2]   PULSATING BUBBLE TECHNIQUE FOR EVALUATING PULMONARY SURFACTANT [J].
ENHORNING, G .
JOURNAL OF APPLIED PHYSIOLOGY, 1977, 43 (02) :198-203
[3]  
ENHORNING G, 1972, PEDIATRICS, V50, P58
[4]   LUNG SURFACTANT - PHOSPHOLIPIDS AND APOPROTEINS - INTRODUCTION [J].
FISHER, AB ;
CHANDER, A .
EXPERIMENTAL LUNG RESEARCH, 1984, 6 (3-4) :171-174
[5]   LUNG SURFACTANT [J].
GOERKE, J .
BIOCHIMICA ET BIOPHYSICA ACTA, 1974, 344 (3-4) :241-261
[6]  
HOIM B, 1987, J APPL PHYSIOL, V63, P1434
[7]  
NOTTER RH, 1985, J APPL PHYSIOL, V57, P326
[8]   Synthesis, purification and surface activities of the human pulmonary surfactant protein-C (SP-C) analogue, SP-CL16 (6-28) [J].
Otsubo, E ;
Takei, T ;
Nomura, M .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2001, 24 (12) :1362-1365
[9]   A PROPOSED NOMENCLATURE FOR PULMONARY SURFACTANT-ASSOCIATED PROTEINS [J].
POSSMAYER, F .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1988, 138 (04) :990-998
[10]  
SEAMUS AR, 1994, FASEB J, V8, P957